Terns Pharmaceuticals Inc Ordinary Shares TERN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if TERN is a good fit for your portfolio.
News
-
This small-cap stock is expected to take off - if its weight-loss pill trial succeeds
-
This small-cap stock is expected to take off - if its weight-loss pill trial succeeds
-
This small-cap stock is expected to take off - if its weight-loss pill trial succeeds
-
Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates
-
Thinking about buying stock in Marathon Digital, Assertio, Ocean Biomedical, Terns Pharmaceuticals, or NextCure?
-
Terns Pharmaceuticals Announces Orphan Drug Designation Granted to TERN-701 for the Treatment of Chronic Myeloid Leukemia
-
Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)
-
Terns Pharmaceuticals to Participate in Upcoming March Investor Conferences
Trading Information
- Previous Close Price
- $6.16
- Day Range
- $6.16–6.75
- 52-Week Range
- $3.26–14.04
- Bid/Ask
- $6.70 / $6.80
- Market Cap
- $424.12 Mil
- Volume/Avg
- 1.2 Mil / 897,478
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 66
- Website
- https://www.ternspharma.com
Comparables
Valuation
Metric
|
TERN
|
IMVT
|
CRNX
|
---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 1.66 | 6.90 | 5.92 |
Price/Sales | — | — | 677.38 |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
Metric
|
TERN
|
IMVT
|
CRNX
|
---|---|---|---|
Quick Ratio | 22.06 | 21.56 | 12.92 |
Current Ratio | 22.39 | 22.14 | 13.07 |
Interest Coverage | — | — | — |
Quick Ratio
TERN
IMVT
CRNX
Profitability
Metric
|
TERN
|
IMVT
|
CRNX
|
---|---|---|---|
Return on Assets (Normalized) | −24.69% | −43.33% | −38.81% |
Return on Equity (Normalized) | −25.89% | −47.83% | −44.79% |
Return on Invested Capital (Normalized) | −29.56% | −52.69% | −45.62% |
Return on Assets
TERN
IMVT
CRNX
Biotechnology Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Gsvpmrdt | Hlbc | $568.9 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Bzhwyvbf | Bntwtp | $108.0 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Dfgxxdvls | Ltrvnst | $105.6 Bil | |
MRNA
| Moderna Inc | Bkkjbpfl | Ypm | $40.8 Bil | |
ARGX
| argenx SE ADR | Srgmzgkb | Dxj | $23.4 Bil | |
BNTX
| BioNTech SE ADR | Kxkkjfw | Hldps | $21.9 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Tmdpmmz | Dckbqpl | $18.8 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Qfswwfdm | Thhfwy | $16.5 Bil | |
RPRX
| Royalty Pharma PLC Class A | Qrsplpchc | Ncvkt | $13.6 Bil | |
INCY
| Incyte Corp | Vrxjjkqvp | Kgnmwhj | $12.8 Bil |